Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients.

Nielsen SA, McDonald MB, Majmudar PA.

Clin Ophthalmol. 2013;7:149-56. doi: 10.2147/OPTH.S38279. Epub 2013 Jan 17. Erratum in: Clin Ophthalmol. 2013;7:725.

2.

Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients.

Majmudar PA, Clinch TE.

Cornea. 2014 May;33(5):457-62. doi: 10.1097/ICO.0000000000000098.

3.

Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.

McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL, Usner DW.

Ophthalmology. 2009 Sep;116(9):1615-1623.e1. doi: 10.1016/j.ophtha.2009.05.014. Epub 2009 Jul 29.

PMID:
19643483
4.
5.

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.

Karpecki P, Depaolis M, Hunter JA, White EM, Rigel L, Brunner LS, Usner DW, Paterno MR, Comstock TL.

Clin Ther. 2009 Mar;31(3):514-26. doi: 10.1016/j.clinthera.2009.03.010.

PMID:
19393842
6.

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study.

Schechter BA, Parekh JG, Trattler W.

J Ocul Pharmacol Ther. 2015 Mar;31(2):114-21. doi: 10.1089/jop.2014.0039. Epub 2014 Nov 19.

PMID:
25409447
7.

Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.

Garg P, Mathur U, Sony P, Tandon R, Morris TW, Comstock TL.

Asia Pac J Ophthalmol (Phila). 2015 May-Jun;4(3):140-5. doi: 10.1097/APO.0000000000000055.

8.

Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.

Yoshida J, Kim A, Pratzer KA, Stark WJ.

J Cataract Refract Surg. 2010 Sep;36(9):1499-502. doi: 10.1016/j.jcrs.2010.04.030.

PMID:
20692561
9.

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.

Bucci FA Jr, Evans RE, Amico LM, Morris TW, Fluet AT, Sanfilippo CM, DeCory HH, Comstock TL.

Clin Ophthalmol. 2015 May 13;9:843-52. doi: 10.2147/OPTH.S83162. eCollection 2015.

10.

Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.

Chang MH, Fung HB.

Clin Ther. 2010 Mar;32(3):454-71. doi: 10.1016/j.clinthera.2010.03.013. Review.

PMID:
20399984
11.
12.

Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.

Comstock TL, Paterno MR, Decory HH, Usner DW.

Clin Drug Investig. 2010;30(10):675-85. doi: 10.2165/11536720-000000000-00000.

PMID:
20629472
13.

The role of besifloxacin in the treatment of bacterial conjunctivitis.

Mahvan TD, Hornecker JR, Buckley WA, Clark S.

Ann Pharmacother. 2014 May;48(5):616-25. doi: 10.1177/1060028014524175. Epub 2014 Feb 24. Review.

PMID:
24566460
15.

The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.

Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C.

Drugs R D. 2013 Dec;13(4):243-52. doi: 10.1007/s40268-013-0029-1.

16.

[New incision versus corneal flap uncover: comparison of two techniques of repeated surgery after primary LASIK in myopia].

Horácková M, Vlková E, Hejcmanová M.

Cesk Slov Oftalmol. 2005 Mar;61(2):96-105. Czech.

PMID:
15898333
17.

Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.

DeLeon J, Silverstein BE, Allaire C, Gearinger LS, Bateman KM, Morris TW, Comstock TL.

Clin Drug Investig. 2012 May 1;32(5):303-17. doi: 10.2165/11632470-000000000-00000.

PMID:
22420526
18.

Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.

Espiritu CR, Caparas VL, Bolinao JG.

J Cataract Refract Surg. 2007 Jan;33(1):63-8.

PMID:
17189795
19.

Laser in situ keratomileusis for refractive error after cataract surgery.

Kim P, Briganti EM, Sutton GL, Lawless MA, Rogers CM, Hodge C.

J Cataract Refract Surg. 2005 May;31(5):979-86.

PMID:
15975465
20.

Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.

O'Brien TP.

Adv Ther. 2012 Jun;29(6):473-90. doi: 10.1007/s12325-012-0027-7. Epub 2012 Jun 20. Review.

PMID:
22729919

Supplemental Content

Support Center